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Aims Several cardiac resident progenitor cell types have been reported for the adult mammalian heart. Here we charac-
terize their frequencies and distribution pattern in non-ischaemic human myocardial tissue and after ischaemic events.
Methods
and results
We obtained 55 biopsy samples from human atria and ventricles and used immunohistological analysis to investigate
two cardiac cell types, characterized by the expression of breast cancer resistance protein (BCRP)/ABCG2 [for side
population (SP) cells] or c-kit. Highest frequencies of BCRP+ cells were detected in the ischaemic right atria with a
median of 5.40% (range: 2.48–11.1%) vs. 4.40% (1.79–7.75%) in the non-ischaemic right atria (P ¼ 0.47). Significantly
higher amounts were identified in ischaemic compared with non-ischaemic ventricles, viz. 5.44% (3.24–9.30%) vs.
0.74% (0–5.23%) (P ¼ 0.016). Few numbers of BCRP+ cells co-expressed the cardiac markers titin, sarcomeric a-
actinin, or Nkx2.5; no co-expression of BCRP and progenitor cell marker Sca-1 or pluripotency markers Oct-3/4,
SSEA-3, and SSEA-4 was detected. C-kit+ cells displayed higher frequencies in ischaemic (ratio: 1:25 000+ 2500
of cell counts) vs. non-ischaemic myocardium (1:105 000+ 43 000). Breast cancer resistance protein+/c-kit+ cells
were not identified. Following in vitro differentiation, BCRP+ cells isolated from human heart biopsy samples
(n ¼ 6) showed expression of cardiac troponin T and a-myosin heavy-chain, but no full differentiation into functional
beating cardiomyocytes was observed.
Conclusion We were able to demonstrate that BCRP+/CD312 cells are more abundant in the heart than their c-kit+ counter-
parts. In the non-ischaemic hearts, they are preferentially located in the atria. Following ischaemia, their numbers are
elevated significantly. Our data might provide a valuable snapshot at potential progenitor cells after acute ischaemia in
vivo, and mapping of these easily accessible cells may influence future cell therapeutic strategies.
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Introduction
Stem cell-based therapies might be therapeutic alternatives for the
restoration of myocardial function after damage or disease, which
are highly desirable as the heart lacks significant endogenous re-
generative potential.1,2 With increasing knowledge of stem cell-
based therapies, new hope has arisen for the treatment of heart
failure. Various stem cell types are undergoing evaluation including
haematopoietic stem cells,3 endothelial progenitors,4 mesenchymal
stem cells (MSCs),5 and the so-called SP cells.6,7 Furthermore,
skeletal myoblasts8 as well as embryonic stem cells (ESC)9 or
induced pluripotent stem cells (iPS)10,11 are being considered.
However, the lack of efficacy, non-specific differentiation, clinical
safety issues as well as the ethical debate over ESC still limit clinical
application and underline the demand for cardiac-specific stem cell
types.
Recent data indicate that the heart hosts its own stem/progeni-
tor cell populations12–14 with the capacity to differentiate along all
cardiac cell lineages.13,15,16 These cardiac resident progenitor cells
(CRPC) include primitive cells expressing the stem-cell-factor
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receptor c-kit (CD117)16, and Sca-1+ cells detected in mice12 and
in humans.17 Despite their frequent denomination as stem cells,
not all these cell types were demonstrated to fulfil the criteria of
bona fide stem cells as being self-renewing, clonogenic, and multi-
potent.18 Martin et al. detected cardiac side population (cSP)
cells in the heart.19 Side population cells can be isolated by dual-
wavelength flow cytometry because of their capacity to efflux
Hoechst dye, a process mediated by the ATP-binding cassette
transporter breast cancer resistance protein (BCRP).6,7 Breast
cancer resistance protein (also known as ABCG2) has been re-
cently reported to play a functional role in modulating the prolifer-
ation, differentiation, and survival of cSP cells,20 but is also present
within endothelial cells of the human heart.21 Another CRPC
population was isolated by Messina et al.22 from murine and
human hearts. They were the first to demonstrate extensive in
vitro proliferation of the isolated cells in so-called cardiosphere cul-
tures. In vitro cultivation of CRPC might be a decisive step forward
for future myocardial restoration requiring large cell numbers.
The expression pattern and frequency of CRPC in a healthy or
diseased human heart has not been explored so far. Herein we
identify and quantify of human BCRP+ and c-kit+ cells in the differ-
ent compartments of the heart and ischaemic vs. non-ischaemic
myocardium, and assess whether human BCRP+ cells can be con-
sidered cardiac progenitor cells. The detailed clarification of the
distribution and frequencies of CRPC in ischaemic and non-
ischaemic heart samples might have an important impact on effect-
ive stem cell treatment strategies in the future.
Methods
Patient demographics
After informed consent, 55 tissue-samples were obtained from 50
patients (male ¼ 32/female ¼ 18). The patients were Caucasians
(17–83 years) and suffered either from ischaemic heart disease (n ¼
33) or non-ischaemic heart-diseases, including valve-disease (n ¼ 13),
non-ischaemic, dilative cardiomyopathy (n ¼ 2), and congenital heart
disease (n ¼ 2). Except three emergency cases including two left ven-
tricular assist device (LVAD) implantations due to ischaemic cardiomy-
opathy (n ¼ 2) and one coronary artery bypass grafting (CABG) for
instable angina (n ¼ 1) within the ischaemic group, and two heart
transplantations due to dilated cardiomyopathy (n ¼ 2) in the non-
ischaemic group, all the patients were elective cases. The treatment
included aspirin, angiotensin-converting enzyme inhibitors, beta-
blockers, and others. The demographics are summarized in Table 1.
Tissue samples
Tissue samples sized 5 × 5 mm were harvested from all areas of the
heart. They were obtained from the right atrium (n ¼ 36) after cannu-
lation during coronary artery bypass grafting (CABG). Endomyocardial
biopsy samples of the left atrium (n ¼ 4), left ventricle (n ¼ 10), and
right ventricle (n ¼ 5) were taken during CABG and all other open
heart procedures. For ischaemic patients, after careful intra-operative
macroscopic evaluation, biopsy samples were harvested from the
border zone of the ischaemic/infarcted area of the left ventricle, but
not directly from the infarcted area. The samples were fixed in 4% par-
aformaldehyde for 2 h following 24 h in 30% sucrose, embedded in Tis-
sueTek (Sakura-Finetek), frozen in liquid nitrogen, and cut into 6-mm
sections.
Immunostaining and cell counts
For a quantitative analysis of progenitor cell frequencies, immunostain-
ing was performed in at least four sections of each tissue sample. The
positive controls were as follows: BCRP+ trophoblast cells in human
placenta (see Supplementary material online, Figure S1A), c-kit+ mela-
nocytes in human skin (see Supplementary material online, Figure S1B),
c-kit+/tryptase+ mast cells in inflammatory skin lesions (see Supple-
mentary material online, Figure S1C–F), and titin+ cells and CD31+
endothelial cells in human cardiac tissue. For pluripotent stem cell
markers Oct-3/4, SSEA-3, and SSEA-4, human-induced pluripotent
stem cell colonies served as positive controls (see Supplementary ma-
terial online, Figure S2). Staining procedures and antibodies used are
described in detail in the Supplementary material online, Methods.
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Table 1 Patient demographics
n 5 50 Ischaemic
(n5 33)
Non-ischaemic
(n 5 17)
Male 26 6
Female 7 11
Height (cm) 171+7 172+7
Weight (kg) 77+12 80+7
BMI 26+4 27+3
EuroScore 4+3 7+4
Ejection fraction 56+13 53+18
Blood pressure systolic
(mmHg)
134+24 136+20
Blood pressure diastolic
(mmHg)
71+17 75+11
Smoker (%) 17 (52) 14 (82)
Positive family history of
any cardiac disease (%)
15 (45) 11 (64)
Diabetes mellitus (%) 9 (27) 5 (29)
Hypertension (%) 14 (42) 12 (70)
Dyslipidaemia (%) 20 (61) 13 (76)
Ischaemic heart disease (%) 33 (100) 0 (0)
Heart valve disease (%) 0 (0) 13 (76)
Dilative cardiomyopathy
(%)
0 (0) 2 (12)
Congenital heart disease
(%)
0 (0) 2 (12)
CABG (%) 23 (70) 0 (0)
Heart valve surgery (%) 0 (0) 13 (76)
Combined heart surgery
(CABG + valve) (%)
8 (24) 0 (0)
Transplantation due to
DCM (%)
0 (0) 2 (12)
LVAD implantation due to
ICM (%)
2 (6) 0 (0)
Congenital heart surgery
(%)
0 (0) 2 (12)
Aspirin (%) 27 (82) 16 (94)
Beta-blockers (%) 11 (33) 8 (47)
ACE inhibitors (%) 4 (12) 3 (18)
CABG, coronary artery bypass grafting; DCM, dilative cardiomyopathy; ICM,
ischaemic cardiomyopathy; LVAD, left ventricular assist device.
All values are mean (+SD).
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Analysis of four slides per tissue sample was performed. At least 12
randomized images per slide were collected with an Olympus-IX81
fluorescence-microscope using a F-View-II camera and the Olympus-
analysisDw software (Olympus; Tokyo, Japan). Images were analysed
with the ImageJw software and the BCRP+ and c-kit+ cell counts were
calculated in at least 12 randomizedmicroscopic fields per slide.We discri-
minated between BCRP+/CD31+ endothelial cells and BCRP+/CD312
cells. Similarly, we discriminated between c-kit+/mast-cell-tryptase+ mast
cells and c-kit+/tryptase2 resident progenitor cells.
Isolation of breast cancer resistance protein1
cells from adult human heart samples
Breast cancer resistance protein+ cells were isolated from human
cardiac tissue samples using collagenase B and dispase II as described
by Pfister et al.23 These procedures are described in detail in the Sup-
plementary material online, Methods.
In vitro differentiation of breast cancer
resistance protein1 cells
The cells were seeded into 24well plates (Nunc/Thermo Fisher Scientific)
after coating with Matrigel (1:30, BD Biosciences, Heidelberg, Germany),
and the cell culturemediumconsistedof 80% IMDM(withGlutamax), 20%
foetal calf serum (HyClone/Thermo Fisher Scientific, Bonn, Germany),
1 mM L-glutamine, 0.1 mM b-mercaptoethanol, 1% non-essential amino
acids, 100 mg/mL penicillin, and 100 mg/mL streptomycin (from PAA
Laboratories, Coelbe, Germany). Twenty-four hours after seeding, the
cells were treated with 100 nM oxytocin (Sigma-Aldrich, Munich,
Germany) for 72 h as described by Oyama et al.24
Gene expression analysis
Quantitative real-time PCR was used to determine the gene expres-
sion of BCRP+ cells after in vitro differentiation. These procedures
are described in detail in the Supplementary material online, Methods.
Statistical analysis
Descriptive data are presented as mean+ standard deviation or
median with range where appropriate. For statistical analysis using
SPSS 18 (SPSS, Inc., Chicago, IL, USA), the Mann–Whitney test was
performed. To avoid biased estimates for patients that provided
more than one cardiac sample (n ¼ 3), medians of samples within
patients were computed and a patient-specific (n ¼ 50) Mann–
Whitney test was performed. Significance was evaluated by two-tailed
testing and assumed to be P, 0.05.
Results
Morphological assessment of putative
progenitor cells detected in the heart
Breast cancer resistance protein+/CD312 cells were identified in
all areas of the heart, appearing mostly small and oval shaped.
They were distributed evenly over the whole microscopic field
(Figure 1A–C ). The major part of these cells did not stain positive
for the cardiac marker titin, but were located either between or in
close relation to the surrounding cardiomyocytes as well as in the
interstitial space. However, also titin-positive BCRP+/CD312
cardiac progenitors could be found, albeit in low numbers
(Figure 1D–F ). Some BCRP+/CD312 cells stained positive for sar-
comeric a-actinin, or the earlier cardiac marker Nkx2.5 for the
identification of cardiac progenitor cells (see Supplementary
material online, Figures S3 and S4). In BCRP+/CD312 cells, we
did not detect staining for the progenitor cell marker Sca-1 (see
Supplementary material online, Figure S5) or pluripotent stem
cell markers Oct-3/4, SSEA-3, and SSEA-4 (see Supplementary ma-
terial online, Figures S6 and S7). Single cells expressing Sca-1 and
Oct-3/4 were observed within the myocardium (see Supplemen-
tary material online, Figures S5 and S6). Cells expressing SSEA-3
or SSEA-4 were detected in vessels and single cells staining positive
for CD31 (see Supplementary material online, Figure S7); however,
we did not analyse these cells further.
Breast cancer resistance protein+/CD31+ cells were also
detected in all areas, representing endothelial cells with the typical
elongated morphology. They were characteristically located in
small capillaries and in the inner wall of arterioles (Figure 1G– I ).
Resident c-kit+ cells were detected both in the ventricles and in
the right atrium. These cells were small and round shaped, without
the typical cardiomyocyte morphology, and did not stain positive
for cardiac markers (Figure 2A–C ).
Distribution and frequencies
Breast cancer resistance protein+/CD312 cells were found more
frequently in ischaemic hearts (n ¼ 33) vs. non-ischaemic (n ¼
22) hearts with a median of 5.38% (range: 2.48–11.1%) vs. 3.57%
(0–7.75%) (P ¼ 0.026) (Figure 3A). In the atria, the highest fre-
quency of BCRP+/CD312 cells was detected in the right atria of
the ischaemic group (n ¼ 26) with a median of 5.40% (2.48–
11.10%) vs. 4.40% (1.79–7.75%) (P ¼ 0.47) in the non-ischaemic
group (n ¼ 10) (Figure 3B). Also in the ventricles, a significantly
increased number of BCRP+/CD312 cells was detected in ischae-
mic ventricles (n ¼ 6) compared with non-ischaemic ventricles
(n ¼ 9) with a median of 5.44% (3.24–9.30%) vs. 0.74% (0–
5.23%), respectively (P ¼ 0.016) (Figure 3C).
The frequency of BCRP+/CD312 cells was analysed with
respect to age and gender. In both the groups (.65 and ≤65
years), BCRP+/CD312 cells were found more frequently in ischae-
mic hearts vs. non-ischaemic hearts (data not shown). Interestingly,
the number of BCRP+/CD312 cells tended to be higher in the age
group .65 years than for patients ≤65 years. This was found for
the ischaemic group with 5.79% (2.48–11.10%) BCRP+/CD312
cells (n ¼ 21) vs. 4.74% (2.51–7.35%) (n ¼ 12), respectively (P ¼
0.24). Similarly, in the non-ischaemic samples, the number of
BCRP+/CD312 cells was 4.17% (3.57–6.23%) (n ¼ 7) in patients
.65 years vs. 1.63% (0–7.75%) (n ¼ 15) in patients ≤65 years
(P ¼ 0.20).
Analysing ischaemic samples from all parts of the heart, we
found a slight tendency towards a higher number of BCRP+/
CD312 cells in female patients than in male patients, viz. 5.42%
(3.54–11.10%) (n ¼ 7) vs. 5.01% (2.48–9.64%) (n ¼ 26);
however, this effect did not reach statistical significance (P ¼ 0.35).
Breast cancer resistance protein+/CD312 cells were analysed
for cardiac differentiation in the heart to investigate whether they
can be considered progenitor cells. In 50% of all tissue-samples,
some BCRP+/CD312 cells stained positive for the cardiac marker
titin, albeit in low numbers [median of 0.36% (0–1.27%) in the
ischaemic heart vs. 0.18% (0–0.39%) in the non-ischaemic heart
(P ¼ 0.013) (Figure 4A)]. The distribution of BCRP+/CD312/titin+
cells was identified as follows: 0.33% (0–0.92%) of cells were
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Figure 1 Breast cancer resistance protein+ cells in the adult human heart. Cryosections of heart tissue were stained with antibodies to breast
cancer resistance protein (red), titin (green), and CD31 (blue). Nuclei were stained with DAPI (white) (×40). Inset shows cells pointed out by
arrows. (A–C) (right atrium/C/61 years): breast cancer resistance protein+/CD312 cells (arrows) presumably representing resident cardiac
progenitors were identified in all areas of the heart. (D–F) (right atrium/F/70 years): A subset of breast cancer resistance protein+/CD312
cells (arrows) stain also positive for the cardiac marker titin (here: 0.50% of total cell numbers). (G– I) (right atrium/F/83 years): breast
cancer resistance protein+/CD31+ cells (arrows) representing endothelial cells could be detected in all areas of the heart, mostly located
in small capillaries and arterioles. Scale bar: 50 mm.
Figure 2 C-kit+ cells in ischaemic human myocardium. Cryosections of adult human heart tissue were stained with antibodies to c-kit (green,
indicated by arrows), titin (red), and mast cell tryptase (blue). Nuclei were stained with DAPI (white). Inset shows cells pointed out by arrows.
(A–C) Tissue sample (left ventricle/F/75 years) after myocardial infarction; very low frequencies of c-kit+/ mast cell tryptase2 cells were
detected (arrow), while no mast cells were observed. Scale bar: 50 mm.
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detected in the ischaemic right atria (n ¼ 26) vs. 0.27% (0.08–
0.39%) in non-ischaemic right atria (n ¼ 10) (P ¼ 0.60) (Figure 4B).
Higher BCRP+/CD312/titin+ cell numbers were detected in is-
chaemic ventricles (n ¼ 6) compared with non-ischaemic ventricles
(n ¼ 9) [median of 0.50% (0.35–1.27%) vs. 0% (0–0.39%; P ¼ 0.005)
(Figure 4C)].
Breast cancer resistance protein+/CD31+ cells, representing
endothelial cells, were also found more frequently in ischaemic
hearts compared with non-ischaemic hearts [median of 5.50%
(0.91–11.98%) vs. 3.14% (0–8.33%); P ¼ 0.04] (see Supplementary
material online, Figure S8). In detail, the distribution pattern of
BCRP+/CD31+ cells was identified as follows: 7.37% (5.51–
11.09%) BCRP+/CD31+ cells were detected in ischaemic ventri-
cles vs. 2.18% (0–6.89%) in non-ischaemic ventricles (P ¼ 0.01).
In contrast to this, the right atria showed almost the same
amount of BCRP+/CD31+ cells in the ischaemic (n ¼ 26) and
Figure 4 Higher frequency of Titin+ subsets of breast cancer resistance protein+/CD312 cardiac resident progenitor cells in the ischaemic
human heart. Distribution and frequencies (percentage of all cardiac cells) of breast cancer resistance protein+/CD312/Titin+ cells in non-
ischaemic vs. ischaemic hearts (A), non-ischaemic vs. ischaemic atria (B) as well as non-ischaemic vs. ischaemic ventricles (C). Graphs are
shown with median and range. In order to avoid biased estimates for patients that provided more than one cardiac sample, a patient specific
Mann–Whitney test was performed.
RA, right atrium.
Figure 3 Higher frequency of cardiac resident breast cancer resistance protein+/CD312 cells in the ischaemic human heart. Distribution and
frequencies (percentage of all cardiac cells) of all breast cancer resistance protein+/CD312 cells in non-ischaemic vs. ischaemic hearts (A), non-
ischaemic vs. ischaemic atria (B) as well as non-ischaemic vs. ischaemic ventricles (C ). Graphs are shown with median and range. To avoid biased
estimates for patients that provided more than one cardiac sample, a patient-specific Mann–Whitney test was performed.
RA, right atrium.
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non-ischaemic groups (n ¼ 10) [5.27% (0.91–11.98%) vs. 4.53%
(2.17–8.33%); P ¼ 0.60].
C-kit+ cells were detected in 30% of the samples and were
found in higher numbers within ischaemic (ratio: 1:25 000+
2500 of cell counts) vs. non-ischaemic myocardium (1:105 000+
43 000) including ventricles and the right atrium. A detailed com-
parison between ischaemic and non-ischaemic ventricles showed
an increased frequency of c-kit+ cells within ischaemic ventricles
(1:25 000+ 2500) vs. either no or only very low numbers of
c-kit+ cells (1:120 000+50 000) within non-ischaemic ventricles.
The cell ratio in ischaemic ventricles increased up to five-fold
(P ¼ 0.022). Although BCRP+ and c-kit+ cells were found in
close proximity (Figure 5), no BCRP+/c-kit+ double-positive cells
were detected.
Isolation and in vitro differentiation of
breast cancer resistance protein1 cells
Using immunomagnetic bead separation, cells were enriched from
dissociated human heart samples (n ¼ 6) on the basis of their ex-
pression of the surface marker BCRP. Co-purified adult human car-
diomyocytes did not adhere to the cell culture dishes (see
Supplementary material online, Figure S9A) and were removed
upon medium exchange. Breast cancer resistance protein+ and
BCRP2 cells were cultivated on matrigel-coated plates in differen-
tiation medium. Breast cancer resistance protein2 cell fractions
showed higher proliferation rates than BCRP+ cells and were fre-
quently overgrown with fibroblast-like cells during cultivation (see
Supplementary material online, Figure S9B–D). To test for differen-
tiation potential as described by Oyama et al.24 in the rat model,
the cells were treated with 100 nM oxytocin for 72 h. However,
no spontaneous beating of isolated cells was observed during cul-
tivation for 21 days (Figure 6A–C).
After 21 days, no cTnTexpressionwas detected in BCRP2 cells by
immunostaining (Figure 6D). In contrast, the majority of BCRP+ cells
stained positive for cTnT (Figure 6E and F ), with a diffuse and/or a
punctuate dotted linear staining pattern (Figure 6F). Interestingly,
BCRP+ cells not treated with oxytocin seemed to display a similar
differentiation capacity, a direct comparison of oxytocin-treated
with untreated cells is given in Supplementary material online,
Figure S10. On Day 21, quantitative real-time PCR detected an
8.3-fold (+2.4) increase in a-myosin heavy chain expression in
oxytocin-treated BCRP+ cells vs. untreated BCRP+ cells (see
Supplementary material online, Figure S10E). However, it has to be
noted that the small sample number and size did not allow statistical
analysis or the evaluation of other markers of cardiac differentiation.
Discussion
It was proposed that the cardiac SP cell population functions as a
progenitor cell population for the development, maintenance, and
Figure 5 No c-kit/breast cancer resistance protein double-positive cells were detected in the adult human heart. Tissue sample (left ven-
tricle/F/53 years) after myocardial infarction, cryosections were stained with antibodies to breast cancer resistance protein (red, indicated
by arrows; A, C, D), c-kit (green, indicated by arrowheads; B, C, D), and titin (blue; D). Nuclei were stained with DAPI (white). Although
breast cancer resistance protein+ and c-kit+ cells were found in close proximity (D), no breast cancer resistance protein+/c-kit+ double-
positive cells were detected. Inset shows cells pointed out by arrows/arrowheads. Scale bar: 50 mm.
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repair of the heart.19 Oyama et al.24 were the first to demonstrate
that cSP cells from post-natal rat hearts can differentiate into spon-
taneously beating cardiomyocytes after induction with
non-toxic/-carcinogenic reagents such as oxytocin, as well as into
other cell lineages, including endothelial cells and smooth muscle
cells. These results support the concept that BCRP+/CD312 SP
cells might be a possible source for regeneration.
Breast cancer resistance protein1 cells
in the adult human heart
In this study, BCRP+/CD312 cells were detected in the atrial tissue
of ischaemic but also in non-ischaemic patients at very similar
levels. From a clinical point of view, the occurrence of CRPC
even in non-ischaemic atria as described by Urbanek et al.25
poses an excellent opportunity for a safe isolation during heart
surgery or even by catheterization. Interestingly, there was a signifi-
cant increase in the number of BCRP+/CD312 cells in ischaemic
compared with non-ischaemic ventricle. These results might
reflect repair mechanisms which are activated after ischaemic
events. In the murine setting, Pfister et al.26 found that in vitro car-
diomyogenic differentiation was observed exclusively in cardiac SP
cells lacking CD31. For the human heart, a potential activation and
mobilization of these CRPC in vivo by a local cytokine application as
proposed by Urbanek et al.25 might be optimized by a detailed
CRPC mapping. The localization of BCRP+ cells in non-ischaemic
atria is in line with previous reports on the special role of the
atria for c-kit+ cells, described as protected niches located in ana-
tomical areas exposed to low levels of wall stress,27 with higher
numbers of cardiac progenitor cells produced from right atrial
tissue than obtained from other parts of the heart.28
Meissner et al.21 reported that ABCG2 is variably expressed in
endothelial cells of the human heart. In our study, BCRP+/
CD31+ endothelial cells24,26 were detected in all areas of the
heart within capillaries and small arterioles. Higher numbers
were detected in ischaemic as well as in non-ischaemic atria and
after myocardial infarction, increased numbers were identified in
the ischaemic area of the ventricle, probably supporting angiogen-
esis. Only a few BCRP+/CD312 cells expressed the cardiac marker
titin. Likewise, individual BCRP+/CD312 cells were found to
express other cardiac markers such as sarcomeric a-actinin and
Nkx2.5; however, their frequency was not quantified in this
study. At the same time, the absence of expression of Oct-3/4,
SSEA-3, and SSEA-4 in BCRP+ cells clearly indicates the lack of
pluripotency. On the basis of these data, we assume that the
BCRP+ cell population described in this study might represent
an already committed mesodermal progenitor state, as described
by Ott et al.29 As we did not detect human BCRP+/Sca-1+ cells,
we conclude that the progenitor cell population described in our
study is not identical to the Sca-1+ progenitor population found
earlier in the human heart.17 However, we cannot rule out hetero-
geneous Sca-1 expression in a subset of human BCRP+ cells, as
was described for the mouse heart.26,30
C-kit1 cells in the adult human heart
Additionally, we were able to confirm the presence of c-kit+
CRPC in the adult myocardium,16,31 with higher frequencies (up
Figure 6 Breast cancer resistance protein+ cells isolated from the adult human heart differentiate in vitro. Morphology of oxytocin-treated
breast cancer resistance protein+ cells on d3 (A), d14 (B), and d21 (C) of cultivation. After 21 days of cultivation, cells were fixed and stained for
cardiac troponin T (cTnT, green). Nuclei were stained with DAPI (blue). While breast cancer resistance protein2 cells did not express cTnT
(D), breast cancer resistance protein+ cells stained positive for cTnT (E and F) with punctuate dotted linear staining pattern, resembling pre-
myofibrils, in oxytocin-treated cells (F). Scale bar: 100 mm.
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to five-fold) in the ischaemic ventricles and much lower numbers in
the non-ischaemic myocardium. A comparison of progenitor cell
frequencies observed in the human heart is difficult. Earlier
reports used a variety of units, e.g. c-kit+ cells per 100 mm2,15,16
c-kit+ cells per cm3 (×103)25,32 (reviewed in,33 there: cells per
mm3), or c-kit+ cells as a percentage of the entire cell popula-
tion.34 The latter publication described a frequency of c-kit+
cells of 1.1+1.0% after enzymatic dissociation of 60 mg myo-
cardial tissue (n ¼ 6). Highest numbers of c-kit+ cells with 8.9+
0.4% were reported for the right atrium of neonatal children
,30 days of age.35 Numbers of c-kit+ cells found in our study in
adult patients are significantly lower, with 0.004% in the non-
ischaemic samples and 0.001% in the ischaemic samples.
However, our data are in line with independent reports on fre-
quencies of c-kit+ cells of 0.002% in the adult human heart.36
C-kit+ resident cells did not stain positive for the cardiac marker
titin. In compliance with the CRPC classification by Anversa
et al.,33 these cell types are considered rather primitive. Further-
more, we could show that there were no c-kit+/BCRP+
co-expressing stem/progenitor cell populations. This suggests
that these two markers are expressed by two distinct cell popula-
tions in the human heart as was already proposed by Anversa
et al.33 for various species.37
In vitro differentiation of breast cancer
resistance protein1 cells isolated from the
adult human heart
Although elevated numbers in ischaemic human heart might indi-
cate a regenerative role for BCRP+ cells, currently there is no
proof of a direct link between progenitor cell numbers and myo-
cardial restoration in vivo. As described for other stem/progenitor
cell types, a variety of mechanisms is possible: The cells could (i)
differentiate into tissue-specific cells, (ii) induce growth and differ-
entiation through secreted factors, (iii) attract immune cells and
affect their cytokine production, or (iv) secrete anti-apoptotic
factors.38 To investigate potential differentiation into cardiomyo-
cytes, first we performed in vitro experiments using BCRP+ cells
isolated from human heart tissue samples. In contrast to reports
from Oyama et al.24 describing spontaneous beating of cardiomyo-
cytes derived from rat SP cells, we did not observe beating of
BCRP+ cells isolated from human heart tissue at any time. This
might be in line with reports by Yamahara et al.,30 who did not
find the generation of spontaneously beating cells from murine
cardiac SP cells. It is currently unknown whether further optimized
culture conditions for individual species and/or prolonged cultiva-
tion periods of .3 weeks could lead to full cardiac differentiation
of human BCRP+ cells. After cultivation for 21 days, we observed
that a majority of BCRP+ cells displayed diffuse staining of troponin
T. Moreover, some cells showed periodically localized foci of
intense labelling. While we did not detect a mature sarcomeric or-
ganization, this staining pattern might represent premyofibrils
before lateral alignment,39 as sometimes observed for early
stages of cardiac differentiation in primate embryonic stem
cells.40 The interesting observation in our study that both
oxytocin-treated and untreated BCRP+ cells displayed troponin
T expression might be explained by the fact that both were
cultivated in differentiation medium containing a distinct lot of
foetal calf serum selected for efficient cardiac differentiation of
human iPS cells. According to our quantitative PCR data, higher
levels of a-myosin heavy chain (MHC) seem to be expressed in
oxytocin-treated BCRP+ cells. However, the small sample
number and size did not allow statistical analysis. Although we
cannot fully exclude the possibility that BCRP+ cell cultures
were contaminated with adult human cardiomyocytes, potentially
contributing to a-MHC expression levels, such a contamination
can be considered unlikely because of the absence of beating
cells at any time. In our setting, troponin T staining in the majority
of cells showed that human BCRP+ cells can adopt some markers
of immature cardiomyocytes in vitro. In contrast to rat cells,24
however, we did not observe full differentiation into functional
beating cardiomyocytes or other cardiac cell types. Therefore, it
remains unclear whether they could represent cardiac progenitor
cells in the human heart. This might argue for fundamental species
differences with respect to differentiation potential and the physio-
logical role of cardiac BCRP+ progenitor cells, similar to differ-
ences in differentiation capacity observed for MSCs or
cardiospheres.22,41 Although the significantly increased number
of those cells in the ischaemic myocardium strongly suggests an im-
portant role in regeneration processes, the formation of functional
de novo myocardium from human cardiac BCRP+ progenitor cells
appears rather unlikely. Clearly, further studies will be needed to
fully characterize the regenerative potential of this interesting cell
population from the adult human heart.
Conclusion
In conclusion, we were able to demonstrate that BRCP+/CD312
cells are more abundant in the human heart than their c-kit+ coun-
terparts. In the non-ischaemic heart, they are preferentially located
in the atria. Following ischaemia, their numbers are increased sig-
nificantly and, most interestingly, the highest change can be
found in the left ventricle. At the same time, also the number of
these BCRP+ cells expressing the cardiac marker titin is highest
in the left ventricle. Breast cancer resistance protein+ cells could
be isolated from the human heart and adopted certain markers
of immature cardiomyocytes in vitro, but without differentiation
into beating cells. Therefore, our data might provide a valuable
snapshot at cardiac progenitor cells after acute ischaemia, even
though absolute numbers of cells acquiring a myocardial pheno-
type are low and the overall impact on cardiac regeneration in
vivo has to be investigated in the future.
Study limitations
In this proof of concept study, the patient cohort displayed certain
heterogeneity, and only a minimal data set was collected for each
patient with regard to demographic profiling. Therefore, in subse-
quent studies when including higher numbers of patients, it may be
of value to correlate more specific patient characteristics (including
complete medication) with the expression and frequencies of
BCRP cells. Additionally, we restricted our study to c-kit+ and
BCRP+ cells and did not evaluate the frequency and distribution
of further cardiac stem and progenitor cell populations such as
Sca-1+ cells.
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Clearly, expression of titin in a subpopulation of human BCRP+
cells in vivo and expression of cardiac troponin T and a-MHC in
vitro indicate that BCRP+ cells acquire certain myocardial charac-
teristics in vivo and might have progenitor potential; however, it is
uncertain whether human BCRP+ cells can form functional beating
cardiomyocytes similar to rat cells. In the case of c-kit+ cells, the
low numbers detected in our study might argue against a pivotal
role in regenerative processes in the human heart. Furthermore,
it has to be noted that the small number and size of myocardial
tissue samples did not allow statistical analysis or the evaluation
of other markers. Further investigation will be needed to thor-
oughly assess the role of human BCRP+ and c-kit+ cells in en-
dogenous cardiac regeneration and their impact on regenerative
therapies.
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Supplementary material is available at European Heart Journal online.
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